Few compounds in the research peptide world have generated as much discussion as BPC-157 — and few have been as consistently misrepresented. This is what the peer-reviewed literature actually says.
What: A 15-amino-acid synthetic peptide derived from a protective protein first identified in human gastric juice.
Research areas: Tendon and ligament healing · Gastric and intestinal protection · Muscle and bone injury models · Neurological injury models · Vascular response
Evidence: Extensive rat and cell-culture studies from Sikiric's Zagreb group over three decades; essentially no peer-reviewed human randomized trials.
Status: Not approved as a medicine anywhere. WADA-prohibited since 2019. Sold as a research chemical only.
What is BPC-157?
BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a protective protein originally identified in human gastric juice. The "parent" protein — referred to in the literature simply as BPC (Body Protection Compound) — was first described by researchers investigating why the gastric environment, which aggressively degrades most proteins, appeared to contain factors that protected the stomach lining itself.
The peptide was first isolated and systematically studied by Professor Predrag Sikiric and colleagues at the University of Zagreb School of Medicine in the 1990s. Sikiric's group has since published hundreds of papers on the compound across more than three decades, making it one of the most heavily researched experimental peptides in the preclinical literature (Sikiric et al., 2018).
The molecule's full amino-acid sequence is:
Chemically, it is a straightforward synthetic pentadecapeptide with no disulfide bridges, no unusual amino acids, and no post-translational modifications. This structural simplicity is part of what makes it unusual: despite its short sequence, published studies report it to be remarkably stable in conditions where most peptides are rapidly degraded.
Proposed mechanisms of action
The literature proposes several overlapping mechanisms through which BPC-157 may exert its effects in animal models. These are described as "proposed" deliberately — most have been characterized in rodents and cell culture, not in human subjects.
Nitric oxide pathway modulation
A recurring theme in Sikiric's research program is the interaction between BPC-157 and the nitric oxide (NO) system. Published studies report that the peptide appears to modulate NO synthesis in rat models, and that many of its observed effects can be attenuated or amplified by co-administration of NO synthase inhibitors or NO precursors (Sikiric et al., 2014).
VEGFR2 and angiogenesis
Several in-vitro studies have reported that BPC-157 upregulates expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and promotes endothelial cell tube formation — a standard model of angiogenesis (the formation of new blood vessels from existing ones). Researchers have proposed this as one potential mechanism behind the tissue-healing effects observed in animal injury models (Hsieh et al., 2017).
Growth hormone receptor upregulation
A 2018 publication from Chang and colleagues reported that BPC-157 exposure increased growth hormone receptor expression in tendon fibroblasts in cell culture. The authors proposed this as a possible link to the tendon-healing effects reported in rat models (Chang et al., 2014).
Fibroblast growth factor interaction
The literature also describes interaction with FGF (fibroblast growth factor) pathways, primarily in the context of wound healing and fibroblast proliferation assays (Seiwerth et al., 2014).
Dopamine, serotonin, and GABA systems
Beyond the periphery, BPC-157 has been studied for interactions with central neurotransmitter systems. Published work from Sikiric's group has reported effects on dopaminergic signaling, serotonergic pathways, and GABA-A receptor function in rat models of neurological injury and behavior (Sikiric et al., 2018).
It is important to read mechanism claims carefully. "BPC-157 modulates the NO pathway in rat models" is a defensible statement from the literature. "BPC-157 works through nitric oxide" is a stronger claim that the evidence does not fully support. The proposed mechanisms are hypotheses being actively investigated, not established pharmacology.
Key research areas
Tendon and ligament research
The tendon and ligament literature is where BPC-157 has generated the most attention outside of academic circles. Studies in rats have reported accelerated healing of transected (surgically cut) Achilles tendons, with histological (tissue-level microscopy) evidence of faster collagen organization and fibroblast infiltration (Krivic et al., 2006). A subsequent study by Chang and colleagues reported enhanced tendon-to-bone healing in a rat detached quadriceps tendon model (Chang et al., 2011).
In cell culture, the peptide has been shown to enhance proliferation and migration of tendon-derived fibroblasts (Chang et al., 2014). These in-vitro results are frequently cited as a mechanistic explanation for the rodent healing studies, though the two lines of evidence have not been fully reconciled with a human-relevant pharmacokinetic picture.
Gastric and intestinal research
Given the peptide's origin in gastric juice, it is unsurprising that some of the earliest and most extensive research involves the gastrointestinal tract. Multiple studies in rat models have reported that BPC-157 is protective against NSAID-induced gastric lesions, including lesions caused by indomethacin, ibuprofen, and aspirin (Sikiric et al., 2018).
Research has also examined effects on inflammatory bowel disease models. A 2013 study from Klicek and colleagues reported amelioration of colitis in a rat DSS-induced model, with reduced histological damage and improved stool parameters (Klicek et al., 2013).
Musculoskeletal research
Beyond tendons, the literature describes studies in muscle crush injury models, transected quadriceps repair, and bone healing. In a rat muscle crush study, researchers reported faster functional recovery in BPC-157-treated animals compared with controls (Novinscak et al., 2008). Bone healing research has included segmental defect models where histological analysis reported improved bone bridging (Keremi et al., 2009).
Neurological research
Tudor and colleagues published a study in 2010 using a rat traumatic brain injury model, reporting that BPC-157 administration was associated with attenuated lesion progression and improved behavioral outcomes (Tudor et al., 2010). Subsequent work from the Sikiric group has examined interactions with GABA systems and effects in haloperidol-induced catalepsy models, proposing dopaminergic involvement (Jelovac et al., 1999).
Cardiovascular research
A smaller but consistent body of work has examined vascular effects, particularly under stress conditions. Published studies have reported effects on endothelial function and on the outcomes of vascular occlusion models in rats, again with the NO pathway proposed as a likely mediator (Sikiric et al., 2016).
Current state of evidence
A sober view of the BPC-157 literature must distinguish between what has been studied and what has been established. The distinction matters.
- Extensive preclinical research. The majority of published work is in rats, with a smaller number of cell culture studies. The volume of this research is genuinely substantial — several hundred papers across the Sikiric group's output alone.
- Very limited human clinical data. Peer-reviewed human randomized controlled trials for BPC-157 are, at the time of writing, essentially absent from the literature for most indications that the peptide is discussed in connection with.
- WADA prohibited list since 2019. The World Anti-Doping Agency added BPC-157 to its prohibited list in 2019, classified under S0 (Non-Approved Substances). This is a regulatory classification, not a statement about efficacy.
- No regulatory approval. BPC-157 is not approved as a medicine by the European Medicines Agency, the MHRA, the FDA, or any comparable regulator. It has no authorized therapeutic indication anywhere in the world.
- Research chemical status. Legally, it is sold as a research chemical for in-vitro and laboratory research purposes only.
Stability and handling
One of the more unusual characteristics reported in the literature is BPC-157's stability. Most peptides are rapidly degraded by gastric acid and digestive proteases — it is the central reason why peptide therapeutics are typically injected rather than taken orally. BPC-157, by contrast, has been reported by Sikiric and colleagues to remain stable in human gastric juice for extended periods in laboratory testing (Veljaca et al., 1995).
Research groups have reported that in lyophilized (freeze-dried) form, the peptide is stable at room temperature over extended storage periods, with shelf lives that are measured in years rather than weeks. Once reconstituted in solution, published stability studies have indicated that refrigerated storage in bacteriostatic water is the standard laboratory approach.
This stability profile is unusual enough that it has itself been the subject of published investigation.
What the research does not show
Being honest about what is not in the literature is as important as cataloging what is. The following statements are supported by the absence of peer-reviewed evidence, not its presence.
- No human randomized controlled trials for most of the indications commonly discussed online.
- Efficacy in humans is speculative. Extrapolation from rodent studies to human outcomes is a well-known source of failure in drug development. Promising rat data frequently does not translate.
- Optimal human dosing is not established. The published literature does not contain properly powered human dose-ranging studies.
- Long-term human safety is uncharacterized. Animal safety data, even where available, does not substitute for human safety data collected over years of follow-up.
- Mechanism is not fully understood. The proposed mechanisms are hypotheses with varying degrees of experimental support, not established pharmacology.
Published dosing ranges
Because this article summarizes published research, it is worth describing what the literature reports about doses used in experiments. These are not instructions, recommendations, or guidance for any kind of use.
In the rodent literature, doses in the range of 10 μg/kg body weight are commonly encountered in rat studies, with variations upward and downward depending on the route of administration and the injury model under investigation. Some studies have used doses as low as 10 ng/kg and others as high as 100 μg/kg to characterize dose-response relationships (Sikiric et al., 2010).
Critically, no established human dosing exists in the peer-reviewed trial literature. Discussions of "human equivalent doses" that appear in non-peer-reviewed sources are typically calculated via allometric scaling (a method of converting doses between species based on body size) from rodent data — a technique that produces rough estimates for regulatory submissions but does not establish safety or efficacy in humans.
This article is a summary of published research. Where dosing is discussed, the context is always: "in published research, doses have varied between X and Y." At no point should this be read as instruction for human use. BPC-157 is not an approved medicine. There is no established human protocol in the peer-reviewed literature.